Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by Sniper007on Apr 28, 2022 8:36pm
300 Views
Post# 34640843

Collaboration with Jansen

Collaboration with JansenCollaboration with Jansen (see link below if it works).

Google Bioaf: Collaboration arrangement with Jansen

"Alternatives that may be pursued include potential accretive merger or acquisition opportunities and future financings."

I talked with IR this week and things do seem to be going very, very, well (Psst - Frt, beenthere, Aarcor, maybe you should do the same). Accretive was definitely a word that was used multiple times. 

Acquisition opportunities scare me at this point in the game given that Bioasis has not yet accomplished anything truly worthy of a sp increase. I would like to hear others thoughts on this report released on tuesday from Zacks.

https://finance.yahoo.com/news/bioaf-collaboration-arrangement-janssen-101500677.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAACef_aMS7lyO4tGhnjmLyGWeNmvV7B0QZEV_p_Rm1k8s9KDdRPj0ZOfLrAumDjDWmsD7UUSgsC0tDxV8qFTJTqZYbwZ4kWPREsS5fgy_HmFlQmjR-z9jdv56jBZ6YAlGNVlEw0OjIWuT1YfofZtPLtsF5ivBX5jWTQ8bzdPGdRJI#:~:text=On%20April%2011th%2C%20Bioasis,develop%20and%20commercialize%20new%20products.
<< Previous
Bullboard Posts
Next >>